• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form 10-Q/A filed by Vicarious Surgical Inc. (Amendment)

    5/13/24 4:05:26 PM ET
    $RBOT
    Industrial Specialties
    Health Care
    Get the next $RBOT alert in real time by email

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

    FORM 10-Q/A

    Amendment No. 1

     

    (Mark One)

    ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

     

    For the quarterly period ended March 31, 2024

     

    OR

     

    ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

     

    For the transition period from                      to                     

     

    Commission File Number: 001-39384

     

    VICARIOUS SURGICAL INC.

    (Exact name of registrant as specified in its charter)

     

    Delaware   87-2678169

    (State or other jurisdiction of

    incorporation or organization)

     

    (I.R.S. Employer

    Identification No.)

         

    78 Fourth Avenue

    Waltham, Massachusetts

      02451
    (Address of principal executive offices)   (Zip Code)

     

    617-868-1700

    Registrant’s telephone number, including area code

     

    Securities registered pursuant to Section 12(b) of the Act:

     

    Title of Each Class   Trading Symbol   Name of Each Exchange on Which Registered
    Class A common stock, $0.0001 par value per share   RBOT   The New York Stock Exchange
    Warrants to purchase one share of Class A common stock, each at an exercise price of $11.50 per share   RBOT WS   The New York Stock Exchange

     

    Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.    Yes ☒ No ☐

     

    Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).    Yes ☒ No ☐

     

    Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

     

    Large accelerated filer ☐ Accelerated filer ☐
    Non-accelerated filer ☒ Smaller reporting company ☒
      Emerging growth company ☒

     

    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

     

    Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).    Yes ☐   No ☒

     

    As of April 21, 2024, the registrant had 156,415,070 shares of Class A common stock outstanding and 19,619,760 shares of Class B common stock outstanding.

     

     

     

     

     

     

    Explanatory Note

     

    This Amendment No. 1 on Form 10-Q/A (the “Amendment”) amends the Quarterly Report on Form 10-Q of Vicarious Surgical Inc. (the “Company”) for the fiscal quarter ended March 31, 2024, which was originally filed with the Securities and Exchange Commission (the “SEC”) on April 29, 2024 (the “Original Filing”). This Amendment is being filed solely to correct an error in the number of shares of Class A common stock outstanding on the cover page of the Original Filing. The correct number of shares of Class A common stock outstanding as of April 21, 2024, is 156,415,070, as indicated on the cover page of this Amendment.

     

    In addition, as required by Rule 12b-15 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), new certifications by the Company’s principal executive officer and principal financial officer are filed herewith as exhibits to this Amendment, under Item 6 hereof, pursuant to Rule 13a-14(a) or 15d-14(a) of the Exchange Act. Because no financial statements have been included in this Amendment and this Amendment does not contain or amend any disclosure with respect to Items 307 and 308 of Regulation S-K, paragraphs 3, 4 and 5 of the certifications have been omitted. The Company is also not including new certifications under Section 1350 of Chapter 63 of Title 18 of the United States Code (18 U.S.C. 1350) (Section 906 of the Sarbanes-Oxley Act of 2002), as no financial statements are being filed with this Amendment.

     

    Other than as expressly set forth herein, this Amendment does not, and does not purport to, amend, update or restate the information in Original Filing or reflect any events that have occurred after the Original Filing was made. Information not affected by this Amendment remains unchanged and reflects the disclosures made at the time as of which the Original Filing was made. No changes have been made to the financial statements of the Company as contained in the Original Filing. Accordingly, this Amendment should be read together with the Original Filing and the Company’s other filings with the SEC.

     

     

     

     

    Item 6. Exhibits.

     

    Exhibit
    Number
      Exhibit Description   Incorporated by
    Reference herein
    from Form or
    Schedule
      Filing Date   SEC File /
    Registration
    Number 
                     
    31.1*   Certification of Principal Executive Officer Pursuant to Rules 12a-14(a) and 15d-14(a) under the Securities Exchange Act of 1934, as Adopted Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.            
               
    31.2*   Certification of Principal Financial Officer and Principal Accounting Officer Pursuant to Rules 12a-14(a) and 15d-14(a) under the Securities Exchange Act of 1934, as Adopted Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.            
                     
    101.INS   Inline XBRL Instance Document.            
                     
    101.SCH   Inline XBRL Taxonomy Extension Schema Document.            
                     
    101.CAL   Inline XBRL Taxonomy Extension Calculation Linkbase Document.            
                     
    101.DEF   Inline XBRL Taxonomy Extension Definition Linkbase Document.            
                     
    101.LAB   Inline XBRL Taxonomy Extension Label Linkbase Document.            
                     
    101.PRE   Inline XBRL Taxonomy Extension Presentation Linkbase Document.            
                     
    104   Cover Page Interactive Data File (formatted as inline XBRL and contained in Exhibit 101)            

     

    * Filed herewith.

     

    1

     

     

    SIGNATURES

     

    Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

     

      VICARIOUS SURGICAL INC.
            
    May 13, 2024 By: /s/ Adam Sachs
        Adam Sachs
        Chief Executive Officer
        (Principal Executive Officer)
         
    May 13, 2024 By: /s/ William Kelly
        William Kelly
        Chief Financial Officer
       

    (Principal Financial Officer and

    Principal Accounting Officer)

     

     

    2

     

     

    true --12-31 Q1 0001812173 0001812173 2024-01-01 2024-03-31 0001812173 rbot:ClassACommonStock00001ParValuePerShareMember 2024-01-01 2024-03-31 0001812173 rbot:WarrantsToPurchaseOneShareOfClassACommonStockEachAtAnExercisePriceOf1150PerShareMember 2024-01-01 2024-03-31 0001812173 us-gaap:CommonClassAMember 2024-04-21 0001812173 us-gaap:CommonClassBMember 2024-04-21 xbrli:shares
    Get the next $RBOT alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $RBOT

    DatePrice TargetRatingAnalyst
    3/4/2022$16.00 → $7.00Overweight → Neutral
    Piper Sandler
    1/7/2022$16.00Outperform
    Credit Suisse
    12/7/2021$15.00Outperform
    Cowen & Co.
    11/5/2021$15.00Buy
    Canaccord Genuity
    10/18/2021$15.00Buy
    BTIG
    10/7/2021$16.00Overweight
    Piper Sandler
    More analyst ratings

    $RBOT
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Vicarious Surgical Advances Toward Design Freeze with Successful In-Vivo Porcine Lab

    Vicarious Surgical (NYSE:RBOT) (the "Company"), a next-generation robotics technology company seeking to improve lives by transforming robotic surgery, today announced the successful completion of an in-vivo porcine lab conducted in December 2025, marking a meaningful step forward in the development of the company's robotic system and reinforcing progress toward system design freeze targeted for the end of 2026. During the lab, surgeons independently completed key elements of a ventral hernia repair using Vicarious Surgical's pre-DV system as part of a limited-scope feasibility assessment. In parallel, the company executed a series of targeted technical evaluations designed to assess syst

    1/12/26 8:30:00 AM ET
    $RBOT
    Industrial Specialties
    Health Care

    Vicarious Surgical Announces Strategic Software Execution Partnership to Streamline Operations

    Vicarious Surgical Inc. (NYSE:RBOT) (the "Company"), a next-generation robotics technology company seeking to improve lives by transforming robotic surgery, today announced that it has entered into a strategic partnership agreement with a global digital engineering and software development services firm. This engagement is a central component of the Company's broader operating model transformation, designed to improve execution, increase development predictability, and reduce operating expenses as reflected in the Company's cash burn guidance, through a more efficient mix of internal and external engineering resources. Under the agreement, the external engineering partner will assume resp

    12/29/25 4:10:00 PM ET
    $RBOT
    Industrial Specialties
    Health Care

    Vicarious Surgical Announces Full Year 2026 Cash Burn Guidance

    Vicarious Surgical Inc. (NYSE:RBOT, RBOT.WS)) (the "Company"), a next-generation robotics technology company seeking to improve lives by transforming robotic surgery, today announced its full-year 2026 cash burn guidance. Vicarious Surgical expects full-year 2026 cash burn of approximately $35 million, representing a $10 million improvement from the Company's recently updated 2025 guidance of $45 million. Cash needs beyond existing cash resources to achieve design freeze on the Vicarious Surgical system are approximately $25 million. The improved guidance reflects a strong continuation of the Company's operational reset. Key drivers include reductions in headcount and external consulting s

    12/15/25 8:30:00 AM ET
    $RBOT
    Industrial Specialties
    Health Care

    $RBOT
    SEC Filings

    View All

    Vicarious Surgical Inc. filed SEC Form 8-K: Leadership Update, Financial Statements and Exhibits

    8-K - Vicarious Surgical Inc. (0001812173) (Filer)

    2/2/26 4:30:35 PM ET
    $RBOT
    Industrial Specialties
    Health Care

    Vicarious Surgical Inc. filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders

    8-K - Vicarious Surgical Inc. (0001812173) (Filer)

    1/9/26 4:53:15 PM ET
    $RBOT
    Industrial Specialties
    Health Care

    SEC Form EFFECT filed by Vicarious Surgical Inc.

    EFFECT - Vicarious Surgical Inc. (0001812173) (Filer)

    12/23/25 12:15:23 AM ET
    $RBOT
    Industrial Specialties
    Health Care

    $RBOT
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    President Sachs Adam David sold $1,367 worth of shares (463 units at $2.95), decreasing direct ownership by 0.96% to 47,885 units (SEC Form 4)

    4 - Vicarious Surgical Inc. (0001812173) (Issuer)

    12/4/25 7:14:04 PM ET
    $RBOT
    Industrial Specialties
    Health Care

    Chief Technology Officer Khalifa Sammy sold $710 worth of shares (239 units at $2.97), decreasing direct ownership by 0.71% to 33,623 units (SEC Form 4)

    4 - Vicarious Surgical Inc. (0001812173) (Issuer)

    12/4/25 7:13:22 PM ET
    $RBOT
    Industrial Specialties
    Health Care

    Chief Technology Officer Khalifa Sammy sold $1,792 worth of shares (653 units at $2.74), decreasing direct ownership by 2% to 33,862 units (SEC Form 4)

    4 - Vicarious Surgical Inc. (0001812173) (Issuer)

    11/21/25 7:28:06 PM ET
    $RBOT
    Industrial Specialties
    Health Care

    $RBOT
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Vicarious Surgical downgraded by Piper Sandler with a new price target

    Piper Sandler downgraded Vicarious Surgical from Overweight to Neutral and set a new price target of $7.00 from $16.00 previously

    3/4/22 4:51:18 AM ET
    $RBOT
    Industrial Specialties
    Health Care

    Credit Suisse initiated coverage on Vicarious Surgical with a new price target

    Credit Suisse initiated coverage of Vicarious Surgical with a rating of Outperform and set a new price target of $16.00

    1/7/22 7:09:02 AM ET
    $RBOT
    Industrial Specialties
    Health Care

    Cowen & Co. initiated coverage on Vicarious Surgical with a new price target

    Cowen & Co. initiated coverage of Vicarious Surgical with a rating of Outperform and set a new price target of $15.00

    12/7/21 7:31:51 AM ET
    $RBOT
    Industrial Specialties
    Health Care

    $RBOT
    Leadership Updates

    Live Leadership Updates

    View All

    Vicarious Surgical Announces Appointment of Joseph Doherty as Chairman of The Board

    Vicarious Surgical Inc. (NYSE:RBOT, RBOT.WS)) (the "Company"), a next-generation robotics technology company seeking to improve lives by transforming robotic surgery, today announced the appointment of Joseph Doherty as Chairman of the Company's Board of Directors (the "Board"). Mr. Doherty has served as a member of the Board since June 2025. "Since joining Vicarious Surgical, I've had the opportunity to work closely with Joe and greatly value his perspective," said Stephen From, Chief Executive Officer. "As Chairman of the Board, he brings a wealth of experience and thoughtful leadership that will serve the Company well. I look forward to partnering with him and the Board as we advance o

    9/25/25 4:15:00 PM ET
    $JNJ
    $RBOT
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Industrial Specialties

    Vicarious Surgical Announces Appointment of Sarah Romano as Chief Financial Officer

    Ms. Romano brings decades of experience with a strong track record in financial strategy and corporate development Vicarious Surgical Inc. ("Vicarious Surgical" or the "Company") (NYSE:RBOT, RBOT WS)), a next-generation robotics technology company seeking to improve lives by transforming robotic surgery, today announced the appointment of Sarah Romano as Chief Financial Officer (CFO), effective April 1, 2025. Ms. Romano will oversee Vicarious Surgical's financial strategy, leveraging decades of financial leadership experience in capital markets. With exceptional strategic acumen, Ms. Romano has a proven record of driving growth and value creation in public companies, particularly in the h

    3/13/25 8:30:00 AM ET
    $RBOT
    Industrial Specialties
    Health Care

    Vicarious Surgical Strengthens Executive Team with Appointment of Randy Clark as Company President

    Vicarious Surgical Inc. ("Vicarious Surgical" or the "Company") (NYSE:RBOT, RBOT WS))), a next-generation robotics technology company seeking to improve patient outcomes as well as both the cost and efficiency of surgical procedures, today announced that Randy Clark has been appointed President effective today, January 29, 2024. As Vicarious Surgical prepares for its next phase of growth following the anticipated finalization of the Vicarious Surgical Version 1.0 System ("V1.0"), the newly established role of President is designed to fortify organizational alignment and focus on the Company's long-term needs and objectives. Reporting to Chief Executive Officer Adam Sachs, Mr. Clark will a

    1/29/24 8:30:00 AM ET
    $RBOT
    Industrial Specialties
    Health Care

    $RBOT
    Financials

    Live finance-specific insights

    View All

    Vicarious Surgical to Report Third Quarter 2025 Financial Results on November 12, 2025

    Vicarious Surgical Inc. ("Vicarious Surgical" or the "Company") (NYSE:RBOT, RBOT WS)), a next-generation robotics technology company seeking to improve lives by transforming robotic surgery, today announced it will now report financial results for the third quarter ended September 30, 2025 after the market closes on Wednesday, November 12, 2025. Company management will host a corresponding conference call beginning at 4:30 p.m. Eastern Time. Investors interested in listening to the conference call may do so by dialing +1 833-470-1428 for domestic callers or +1 404-975-4839 for international callers, using access code: 623856. A live and archived webcast of the event will be available at ht

    11/6/25 6:13:00 PM ET
    $RBOT
    Industrial Specialties
    Health Care

    Vicarious Surgical to Report Third Quarter 2025 Financial Results on November 13, 2025

    Vicarious Surgical Inc. ("Vicarious Surgical" or the "Company") (NYSE:RBOT, RBOT WS)), a next-generation robotics technology company seeking to improve lives by transforming robotic surgery, today announced it will report financial results for the third quarter ended September 30, 2025 after the market closes on Thursday, November 13, 2025. Company management will host a corresponding conference call beginning at 4:30 p.m. Eastern Time. Investors interested in listening to the conference call may do so by dialing +1 833-470-1428 for domestic callers or +1 404-975-4839 for international callers, using access code: 623856. A live and archived webcast of the event will be available at https:

    10/30/25 4:05:00 PM ET
    $RBOT
    Industrial Specialties
    Health Care

    Vicarious Surgical Reports Second Quarter 2025 Financial Results

    Vicarious Surgical Inc. ("Vicarious Surgical" or the "Company") (NYSE:RBOT, RBOT WS)), a next-generation robotics technology company seeking to improve lives by transforming robotic surgery, today announced financial results for the second quarter ended June 30, 2025. Management will host a corresponding conference call at 4:30 p.m. ET today, August 12, 2025. "Leading Vicarious Surgical from its earliest days through key development milestones has been an extraordinary experience. I'm incredibly proud of the foundation we've built. As I move into the role of President, I'm pleased to welcome Stephen as CEO," said Adam Sachs, President, Co-Founder, and Board member. "His depth of experienc

    8/12/25 4:15:00 PM ET
    $RBOT
    Industrial Specialties
    Health Care

    $RBOT
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G/A filed by Vicarious Surgical Inc. (Amendment)

    SC 13G/A - Vicarious Surgical Inc. (0001812173) (Subject)

    2/13/24 4:36:42 PM ET
    $RBOT
    Industrial Specialties
    Health Care

    SEC Form SC 13G/A filed by Vicarious Surgical Inc. (Amendment)

    SC 13G/A - Vicarious Surgical Inc. (0001812173) (Subject)

    8/15/23 10:28:36 AM ET
    $RBOT
    Industrial Specialties
    Health Care

    SEC Form SC 13D/A filed by Vicarious Surgical Inc. (Amendment)

    SC 13D/A - Vicarious Surgical Inc. (0001812173) (Subject)

    8/9/23 5:10:57 PM ET
    $RBOT
    Industrial Specialties
    Health Care